Your browser doesn't support javascript.
loading
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study.
Shah, Taimur T; Reddy, Deepika; Peters, Max; Ball, Daniel; Kim, Na Hyun; Gomez, Enrique Gomez; Miah, Saiful; Evans, David Eldred; Guillaumier, Stephanie; van Rossum, Peter S N; Van Son, Marieke J; Hosking-Jervis, Feargus; Dudderidge, Tim; Hindley, Richard; Emara, Amr; McCracken, Stuart; Greene, Damian; Nigam, Raj; McCartan, Neil; Valerio, Massimo; Minhas, Suks; Afzal, Naveed; Lewi, Henry; Ogden, Chris; Persad, Raj; Virdi, Jaspal; Moore, Caroline M; Arya, Manit; Emberton, Mark; Ahmed, Hashim U; Winkler, Mathias.
Afiliação
  • Shah TT; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK. t.shah@imperial.ac.uk.
  • Reddy D; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. t.shah@imperial.ac.uk.
  • Peters M; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Ball D; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Kim NH; Department of Radiation Oncology, University Medical Centre, Utrecht, The Netherlands.
  • Gomez EG; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Miah S; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Evans DE; Reina Sofia University Hospital/IMIBIC/University of Cordoba, Cordoba, Spain.
  • Guillaumier S; Department of Urology, Buckinghamshire NHS Trust, Wycombe Hospital, Wycombe, UK.
  • van Rossum PSN; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Van Son MJ; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Hosking-Jervis F; Department of Surgery and Interventional Sciences, University College London, and University College Hospital, London, UK.
  • Dudderidge T; Department of Radiation Oncology, University Medical Centre, Utrecht, The Netherlands.
  • Hindley R; Department of Radiation Oncology, University Medical Centre, Utrecht, The Netherlands.
  • Emara A; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
  • McCracken S; Department of Urology, University Hospital Southampton NHS Trust, Southampton, UK.
  • Greene D; Department of Urology, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
  • Nigam R; Department of Urology, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
  • McCartan N; Department of Urology, Sunderland Royal Hospital, Sunderland, UK.
  • Valerio M; Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Minhas S; Department of Urology, Spire Washington Hospital, Washington, UK.
  • Afzal N; Department of Urology, Royal Surrey NHS Foundation Trust, Guildford, UK.
  • Lewi H; Department of Surgery and Interventional Sciences, University College London, and University College Hospital, London, UK.
  • Ogden C; Urology Department, Lausanne University Hospital, Lausanne, Switzerland.
  • Persad R; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Virdi J; Department of Urology, Dorset County Hospital NHS Trust, Dorchester, UK.
  • Moore CM; Department of Urology, Springfield Hospital, Chelmsford, UK.
  • Arya M; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Emberton M; Department of Urology, North Bristol NHS Trust, Westbury on Trym, Bristol, UK.
  • Ahmed HU; Department of Urology, The Princess Alexandra Hospital NHS Trust, Harlow, UK.
  • Winkler M; Department of Surgery and Interventional Sciences, University College London, and University College Hospital, London, UK.
Prostate Cancer Prostatic Dis ; 24(2): 567-574, 2021 06.
Article em En | MEDLINE | ID: mdl-33504940
INTRODUCTION: Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). METHODS: Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata / Crioterapia Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Assunto da revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata / Crioterapia Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Assunto da revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido